Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.

Abstract

BACKGROUND:

For oligometastatic lung adenocarcinoma patients with sensitive epidermal growth factor receptor (EGFR) mutations, the role of local consolidative therapy (LCT) remains debatable. The purpose of this study was to investigate the efficacy of LCT in oligometastatic lung adenocarcinoma patients.

PATIENTS AND METHODS:

We conducted a retrospective study to assess the effects of LCT on progression-free survival (PFS) and overall survival (OS). Patients with advanced-stage oligometastatic lung adenocarcinoma harboring sensitive mutation of epidermal growth factor receptor (EGFR) who received EGFR-tyrosine kinase inhibitor (TKI) or EGFR-TKI plus LCT were admitted to Shanghai Chest Hospital from January 2010 to December 2016. The PFS and OS of the 2 groups were accordingly analyzed.

RESULTS:

A total of 231 patients (143 patients who received LCT plus EGFR-TKI [combination group] and 88 patients who only received EGFR-TKI only [monotherapy group]) were included in this study. Median PFS was significantly longer in the combination group (15 months; 95% confidence interval [CI], 13.611-16.389) than in the monotherapy group (10 months; 95% CI, 8.936-11.064; hazard ratio = 0.610; 95% CI, 0.461, 0.807; P = .000). The median OS in the combination group was 34 months (95% CI, 27.889, 40.111) versus 21 months (95% CI, 18.445, 23.555) in the monotherapy group (hazard ratio = 0.593; 95% CI, 0.430-0.817; P = .001).

CONCLUSION:

LCT combined with TKIs therapy was a feasible method that significantly improved PFS and OS among oligometastatic lung adenocarcinoma patients with EGFR mutations, and it thus might be considered as an important medical treatment during clinical management.

• Authors: Fang Hu, Jianlin Xu, Bo Zhang, Changhui Li, Wei Nie, Ping Gu, Ping Hu, Huimin Wang, Yujun Zhang, Yinchen Shen, Shuyuan Wang, Xueyan Zhang
• Journal: Clinical lung cancer (Clin Lung Cancer) Vol. 20 Issue 1 Pg. e81-e90 (01 2019) ISSN: 1938-0690 [Electronic] United States
• PMID: 30341018 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Crown Ethers
• Protein Kinase Inhibitors
• Quinazolines
• icotinib
• Erlotinib Hydrochloride
• EGFR protein, human
• ErbB Receptors
• Gefitinib

Topics

• Adenocarcinoma of Lung (mortality, therapy)
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Consolidation Chemotherapy
• Crown Ethers (therapeutic use)
• ErbB Receptors (antagonists & inhibitors, genetics)
• Erlotinib Hydrochloride (therapeutic use)
• Female
• Gefitinib (therapeutic use)
• Humans
• Lung Neoplasms (mortality, therapy)
• Male
• Middle Aged
• Mutation (genetics)
• Neoplasm Metastasis
• Pneumonectomy
• Protein Kinase Inhibitors (therapeutic use)
• Quinazolines (therapeutic use)
• Radiosurgery
• Retrospective Studies
• Survival Analysis